CYP3A5 and systemic lupus erythematosus: A study on SLE patients with CYP3A5 polymorphism (rs776746) to the tacrolimus response, showed that the phenotype of the polymorphism classified into PMs so that there was an increase in drug level on the mutant homozygote compared to the wild type (Ito et al., 2017).